7th Annual Jefferson Liver Disease Symposium
IMPORTANT BROWSER INFORMATION
This site will not work on Internet Explorer 8. Please use:
The 7th Annual Jefferson Liver Disease Symposium 2021 is a one day, virtual program that focuses on relevant information regarding new developments in Hepatology, and new approaches to the management of liver diseases that can be readily integrated into daily practice of gastroenterologists, primary care physicians, nurses, and other members of the healthcare team. Experts in the fields of Hepatology, gastroenterology, and surgery will share their expertise and new findings on a broad range of topics including hepatitis disorders, miscellaneous liver disorders, and liver transplant-related topics.
The keynote speaker at this event is Dr. Hugo E. Vargas. He is a professor of medicine and a consultant for the Division of Gastroenterology and Hepatology, Department of Internal Medicine at the Mayo Clinic, Phoenix, Arizona.
His interest include the manner in which Hepatitis C Virus (HCV) injures liver grafts after transplantation, the effect of the immunosuppressive regimen on viral behavior after liver transplantation, and the hypothesis that HCV infects the brain in patients who do not have immune impairment. Read more
Dr. Vargas will be speaking on HCV: A ‘20/20’ Vision of Treatment Progress and Viral Eradication Efforts.
Key agenda categories will focus on:
- Hepatitis Disorders and Liver Cancer
- Liver Failure and Transplantation
- Miscellaneous Liver Disorders
To successfully complete this activity, the required evaluation must completed by the stated date. Thereafter, the evaluation will no longer be available and credits will not be issued. No refunds will be offered for failure to complete the required evaluation by the stated deadline.
- Pharmacists must complete the required evaluation no later than Monday, May 10, 2021. This is to allow time for upload into CPD Monitor.
- All other attendees must complete the required evaluation must be completed no later Tuesday, May 25, 2021.
This course is designed for gastrointestinal specialists, primary care physicians, internists, surgeons and nurse practitioners, and nurses who treat or manage patients with liver disorders.
Following this educational symposium, learners will be able to:
Topic Area 1: Hepatitis Disorders and Liver Cancer
- Employ current universal screening recommendation for advanced fibrosis in all patients with prediabetes or T2D with steatosis or elevated ALT.
- Discuss potential pharmacologic agents that have pathophysiologic disease targets in NASH.
- Compare the history of HBV treatments to current treatment options.
- Employ current guidelines for testing, diagnosing, and treating patients with chronic hepatitis B.
- Interpret current DILI practice guidelines and guidance statements.
Topic Area 2: Liver Failure and Transplantation
- Use the current pharmacologic and loco-regional treatments for HCC.
- Examine the differential diagnosis of unique liver disorders affecting pregnant women.
- Recognize the structural forces that promote inequity in medicine and healthcare.
- Review telemedicine to manage the care and evaluation of hepatology patients.
- Differentiate HFE from non-HFE causes of iron overload.
- Examine diagnostic testing and therapeutic options for HFE from non-HFE.
Topic Area 3: Miscellaneous Liver Disorders
- Compare latest concepts and treatment to support spontaneous CE survival.
- Recognize how the SARS-CoV-2 virus can affect the liver.
- Analyze SARS-CoV-2 virus impact on the liver transplantation field.
- Explain what’s new in the field of Liver Transplant Organ Allocation.
- Describe the new organ allocation system that was introduced in February 2019.
- Employ the CDC recommendation on universal hepatitis C screening for all U.S. adults and all pregnant women during every pregnancy.
- Examine the various HCV elimination strategies that are being adopted by a variety of nations around the world.
Any sponsorship received for this educational activity will be published and announced prior to the start of the activity.
Participants who register for the program will be sent an email with instructions for accessing the zoom webinar.
Using the link provided in the email, participants must 'register' through zoom to access the program (via the zoom platform). Please use the same name as when registering for the activity to help with verifying participation.
The zoom link will be active 60 minutes prior to the start of the program.
Please click here to send an email if you encounter any problems accessing the program.
Dr. David Sass is a Jefferson University physician and the Medical Director
|Dr. Anthony DiMarino is a Jefferson University physician and the Chair, Division of Gastroenterology and Hepatology|
Director, Celiac Center. He specializes in Gastroenterology and Gastroenterology -
Thomas Jefferson University endorses the ACCME Standards for Commercial Support: Standards to Ensure Independence in CME Activities and the policies that supplement the Standards. All planners, faculty, authors, presenters, and content reviewers are required to disclose any relevant financial relationships with ACCME defined commercial interest entities within the past 12 months. Any conflict of interests have been resolved prior to this educational activity.
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the US FDA for the treatment of disease(s).
Such disclosures will be available prior to the start of the activity. Jefferson Conflict of Interest resolution process may result in changes to the program agenda.
David A. Sass, MD, FAASLD-Course Director
Anthony J. DiMarino, Jr., MD-Course Director
Ann Burke, CRNP
Sarah Yeager, PharmD
Presenters are required to disclose at the start of their session if their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.
In support of improving patient care, Thomas Jefferson University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: This educational activity is designated for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: Nurses will be awarded 6.25 nursing contact hours.
Pharmacists: This knowledge-based continuing education activity is designated for 6.25 contact hours of continuing education credit.
Credits will be uploaded to CPE Monitor within 60 days following the completion of this activity.
This statement contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
Other Professionals: This educational activity is designated for 6.25 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Pharmacology Credit: Content in this educational activity qualifies for 1.67 nursing pharmacology credits. Qualifying sessions:
- NASH Treatment: 2021 and Beyond
- Update in Drug-induced Liver Injury
- Hepatocellular Carcinoma: 2021 Update on Pharmacologic and Loco-Regional Treatment
- Update in Iron Overload Disorders
PA Patient Safety and Risk Credit: Content in this educational activity qualifies for 0.25 PA patient safety and risk credit. Qualifying session:
- Improving Access to Care: the Evolving Role of Telemedicine in a Hepatology Practice
- 6.25 ACPE
- 6.25 AMA PRA Category 1 Credit™
- 6.25 Attendance
- 6.25 CNE
- 1.67 CNE Pharmacotherapy
- 0.25 Patient Safety
|International Physicians/Nurses/Other Health Professional||$125|
|Nurse/Other Health Professionals||$80|
|Jefferson Digestive Disease Network and Jefferson Health Physicians, Nurse and Other Health Professionals||$0|
|All Residents and Fellows||$0|
*Subject to verification.
To register online, you must have a CPD @ JeffLearn account.
RECORDING AND PHOTOGRAPHY STRICTLY PROHIBITED
Unauthorized recording or photography at a Jefferson-sponsored event is strictly prohibited. Individuals found violating this policy will be removed from the online activity or asked to leave from the live activity. No credits or refund will be issued.